keyword
https://read.qxmd.com/read/38621351/inhibition-of-the-renin-angiotensin-system-improves-response-to-neoadjuvant-therapy-in-patients-with-liver-metastasis-of-colorectal-cancers
#1
JOURNAL ARTICLE
Naita M Wirsik, Pia C Appel, Alexander Braun, Moritz J Strowitzki, Nikolai Schleussner, Henrik Nienhüser, Martin Schneider, Thomas Schmidt
INTRODUCTION: Renin-angiotensin-aldosterone system inhibitors (RAAS-I) have been shown to prolong overall survival in patients with liver metastasized colorectal cancer in combination with antiangiogenic treatment. The effects of RAAS-I combined with neoadjuvant chemotherapy on colorectal cancer liver metastasis remain unexplored. We aimed to study the response of patients undergoing liver resection to RAAS-I in combination with neoadjuvant therapy to elucidate their potential benefits...
April 14, 2024: Journal of Surgical Research
https://read.qxmd.com/read/38153512/intravitreal-ranibizumab-injection-is-associated-with-an-increased-risk-of-chronic-kidney-disease-a-population-based-study-in-taiwan
#2
JOURNAL ARTICLE
Chang-Hsu Chen, Paik Seong Lim, Tsai-Kun Wu, Wu-Lung Chuang, Teng-Shun Yu, Fuu-Jen Tsai, Chuan-Mu Chen, Kuang-Hsi Chang
Systemic vascular endothelial growth factor (VEGF) blockade has been the top adjunctive chemotherapy since 1990. Anti-VEGF therapy has also been associated with worsened renal function in some patients. However, the association between patient outcomes and use of intravitreal VEGF inhibitors remains controversial. Thus, it is necessary to determine the action mechanism and long-term renal effects of ranibizumab. The National Health Insurance Research Database (NHIRD) is one of the largest global databases that are extensively used for epidemiological research...
December 28, 2023: Naunyn-Schmiedeberg's Archives of Pharmacology
https://read.qxmd.com/read/38113278/choroidal-amelanotic-mass-with-vermiform-margins-vision-loss-and-extreme-fatigue
#3
JOURNAL ARTICLE
Eleni K Konstantinou, Kevin R Card, Carol L Shields
PURPOSE: To describe a case of a previously healthy middle-aged male with an atypical choroidal mass and fatigue. METHODS: Case report. RESULTS: A 56-year-old Caucasian male presented with decreased vision in the right eye (OD) and a choroidal amelanotic mass OD with subretinal fluid. He received bevacizumab (1.25 mg/0.05 mL) injections by multiple providers without improvement in vision and with tumor progression. Visual acuity was 20/400 OD and 20/25 left eye (OS)...
November 22, 2023: Retinal Cases & Brief Reports
https://read.qxmd.com/read/37905291/management-of-bevacizumab-induced-proteinuria-using-an-angiotensin-receptor-blocker-arb-in-a-neurofibromatosis-type-2-nf-2-patient-with-vestibular-schwannoma
#4
Egiroh E Omene, Jay Easaw
Neurofibromatosis type 2 (NF-2) is a genetic condition that by definition includes bilateral vestibular schwannoma, a non-malignant lesion also known as acoustic neuroma. Patients often develop hearing impairment and hearing loss as a result of the involvement of the vestibulocochlear nerve bilaterally as well as attempts at surgical repair. A common treatment for NF-2-mediated schwannoma is the antiangiogenic agent, bevacizumab. In many cases, patients require prolonged and even lifelong treatment with bevacizumab to control schwannoma growth...
September 2023: Curēus
https://read.qxmd.com/read/37561756/bevacizumab-induced-proteinuria-and-its-association-with-antihypertensive-drugs-a-retrospective-cohort-study-using-a-japanese-administrative-database
#5
JOURNAL ARTICLE
Anna Kiyomi, Fukiko Koizumi, Shinobu Imai, Hayato Yamana, Hiromasa Horiguchi, Kiyohide Fushimi, Munetoshi Sugiura
Proteinuria is a major side-effect of the anti-tumor drug bevacizumab, although its incidence and risk factors in the real world are still unclear. Although renin-angiotensin-aldosterone system inhibitors are used clinically to prevent proteinuria, their efficacy remains unclear. The aim of the present study was to reveal the incidence and risk factors of bevacizumab-induced proteinuria and examine the effectiveness of antihypertensive drugs in preventing proteinuria. We conducted a retrospective cohort study using the National Hospital Organization Clinical Data Archives and Medical Information Analysis Databank...
2023: PloS One
https://read.qxmd.com/read/37439024/renal-implications-of-long-term-systemic-bevacizumab-for-recurrent-respiratory-papillomatosis
#6
JOURNAL ARTICLE
Cal H Robinson, Michael Hart-Matyas, Daniel A Morgenstern, Damien Noone, Paolo Campisi
BACKGROUND: Bevacizumab is a vascular endothelial growth factor (VEGF) inhibitor that is used off-label for select cases of recurrent respiratory papillomatosis (RRP) that are severe, involve the distal airway or lung parenchyma, and refractory to other forms of adjuvant therapy. However, there is limited safety data for the use of bevacizumab in children and VEGF inhibitors are reported to have a range of adverse renal effects, including hypertension, proteinuria, and thrombotic microangiopathy (TMA)...
July 12, 2023: Annals of Otology, Rhinology, and Laryngology
https://read.qxmd.com/read/36401084/enhancing-the-anti-angiogenic-effect-of-bevacizumab-with-ace-inhibition-on-mcrc
#7
JOURNAL ARTICLE
Efe Cem Erdat, Elif Berna Koksoy, Gungor Utkan
INTRODUCTION: Angiotensin 2 has been shown to promote angiogenesis through multiple pathways. Reduction of angiotensin 2 production by angiotensin-converting enzyme inhibitors (ACEi) could enhance the antiangiogenic effect of bevacizumab and lead to improved survival. METHODS: Data from metastatic colorectal cancer (mCRC) patients treated with bevacizumab in our hospital were retrospectively collected. Patients were divided into groups taking ACEi or angiotensin receptor blockers (ARB) or neither...
November 19, 2022: Journal of Gastrointestinal Cancer
https://read.qxmd.com/read/35976221/effects-of-intravitreal-bevacizumab-therapy-on-glomerular-filtration-rates-in-patients-treated-for-proliferative-diabetic-retinopathy
#8
JOURNAL ARTICLE
David A Camp, David A Price, Ashley E Neiweem, Denis Jusufbegovic
PURPOSE: To assess whether the repeated use of intravitreal bevacizumab injections in treatment of proliferative diabetic retinopathy is associated with a long-term decline in the glomerular filtration rate (GFR). METHODS: Three hundred charts were retrospectively reviewed, of which 60 patients met the criteria for inclusion. The criteria were as follows: reception of at least one bevacizumab injection, baseline GFR before initial bevacizumab injection, and end GFR 6 to 24 months after baseline...
October 1, 2022: Retina
https://read.qxmd.com/read/35847929/inhibition-of-angiogenesis-and-extracellular-matrix-remodeling-synergistic-effect-of-renin-angiotensin-system-inhibitors-and-bevacizumab
#9
JOURNAL ARTICLE
Tianshu Ren, Hui Jia, Qiong Wu, Yan Zhang, Qun Ma, Dong Yao, Xudong Gao, Danni Xie, Zihua Xu, Qingchun Zhao, Yingshi Zhang
Bevacizumab (Bev) is a humanized vascular endothelial growth factor monoclonal antibody that is used with chemotherapeutic drugs for the treatment of metastatic colorectal cancer (mCRC). Bev-induced hypertension (HT) is the most common adverse reaction during clinical practice. However, at present, appropriate antihypertensive agents for Bev-induced HT are unavailable. In this study, retrospective analysis of clinical data from mCRC patients who received renin-angiotensin system inhibitors (RASIs) showed significant survival benefits of overall survival (OS) and progression-free survival (PFS) over patients who received calcium channel blockers (CCBs) and patients who received no antihypertensive drug (NO: Y2020046 retrospectively registered)...
2022: Frontiers in Oncology
https://read.qxmd.com/read/35804826/basal-vegf-a-and-ace-plasma-levels-of-metastatic-colorectal-cancer-patients-have-prognostic-value-for-first-line-treatment-with-chemotherapy-plus-bevacizumab
#10
JOURNAL ARTICLE
M José Ortiz-Morales, Marta Toledano-Fonseca, Rafael Mena-Osuna, M Teresa Cano, Auxiliadora Gómez-España, Juan R De la Haba-Rodríguez, Antonio Rodríguez-Ariza, Enrique Aranda
The identification of factors that respond to anti-angiogenic therapy would represent a significant advance in the therapeutic management of metastatic-colorectal-cancer (mCRC) patients. We previously reported the relevance of VEGF-A and some components of the renin-angiotensin-aldosterone system (RAAS) in the response to anti-angiogenic therapy in cancer patients. Therefore, this prospective study aims to evaluate the prognostic value of basal plasma levels of VEGF-A and angiotensin-converting enzyme (ACE) in 73 mCRC patients who were to receive bevacizumab-based therapies as a first-line treatment...
June 21, 2022: Cancers
https://read.qxmd.com/read/34593362/the-misunderstood-link-between-sars-cov-2-and-angiogenesis-a-narrative-review
#11
REVIEW
G Madureira, R Soares
Novel Coronavirus Disease 2019 (Covid-19) is associated with multi-systemic derangement, including circulatory dysfunction with features of endothelial dysfunction, microangiopathic thrombosis and angiocentric inflammation. Recently, intussusceptive angiogenesis has been implicated in the pathogenesis of the disease. Herein, we conducted a narrative review according to the SANRA guidelines to review and discuss data regarding splitting angiogenesis including mechanisms, drivers, regulators and putative roles...
August 27, 2021: Pulmonology
https://read.qxmd.com/read/32571093/low-dose-bevacizumab-decreases-ocular-hypotensive-effect-of-angiotensin-ii-in-sprague-dawley-rats
#12
JOURNAL ARTICLE
J Skrzypecki, K Ciepiaszuk, M Gawryś-Kopczyńska
PURPOSE: Although the effectiveness of anti-VEGF agents in ophthalmology has been thoroughly documented, we do not fully comprehend the epidemiology and mechanistic background of their side effects, including intraocular and systemic hypertension. Here, we investigate the interference of a low-dose bevacizumab with key neuronal and humoral mechanisms maintaining blood and intraocular pressure homeostasis. MATERIALS AND METHODS: Intraocular pressure (IOP), blood pressure (BP), and heart rate (HR) were measured in SPRD rats pretreated with bevacizumab or 0...
June 22, 2020: Current Eye Research
https://read.qxmd.com/read/32523310/treatment-of-gastrointestinal-bleeding-in-left-ventricular-assist-devices-a-comprehensive-review
#13
REVIEW
Srikanth Vedachalam, Gokulakrishnan Balasubramanian, Garrie J Haas, Somashekar G Krishna
Left ventricular assist devices (LVAD) are increasingly become common as life prolonging therapy in patients with advanced heart failure. Current devices are now used as definitive treatment in some patients given the improved durability of continuous flow pumps. Unfortunately, continuous flow LVADs are fraught with complications such as gastrointestinal (GI) bleeding that are primarily attributed to the formation of arteriovenous malformations. With frequent GI bleeding, antiplatelet and anticoagulation therapies are usually discontinued increasing the risk of life-threatening events...
May 28, 2020: World Journal of Gastroenterology: WJG
https://read.qxmd.com/read/32516590/reduction-of-liver-metastasis-stiffness-improves-response-to-bevacizumab-in-metastatic-colorectal-cancer
#14
JOURNAL ARTICLE
Ying Shen, Xiaohong Wang, Junyan Lu, Martin Salfenmoser, Naita Maren Wirsik, Nikolai Schleussner, Andrea Imle, Aida Freire Valls, Praveen Radhakrishnan, Jie Liang, Guoliang Wang, Thomas Muley, Martin Schneider, Carmen Ruiz de Almodovar, Alba Diz-Muñoz, Thomas Schmidt
Tumors are influenced by the mechanical properties of their microenvironment. Using patient samples and atomic force microscopy, we found that tissue stiffness is higher in liver metastases than in primary colorectal tumors. Highly activated metastasis-associated fibroblasts increase tissue stiffness, which enhances angiogenesis and anti-angiogenic therapy resistance. Drugs targeting the renin-angiotensin system, normally prescribed to treat hypertension, inhibit fibroblast contraction and extracellular matrix deposition, thereby reducing liver metastases stiffening and increasing the anti-angiogenic effects of bevacizumab...
June 8, 2020: Cancer Cell
https://read.qxmd.com/read/31576778/advances-in-treatment-of-acute-sulfur-mustard-poisoning-a-critical-review
#15
REVIEW
Leila Etemad, Mohammad Moshiri, Mahdi Balali-Mood
Sulfur mustard (SM) is a blistering chemical warfare agent that was used during the World War I and in the Iraq-Iran conflict. The aim of this paper is to discuss and critically review the published results of experiments on the treatment of SM poisoning based on our clinical and research experience. The victims must remove from the contaminated zone immediately. The best solution for decontamination is large amounts of water, using neutral soap and 0.5% sodium hypochlorite. Severely intoxicated patients should be treated according to advanced life support protocols and intensive care therapy for respiratory disorders and the chemical burn...
March 2019: Critical Reviews in Toxicology
https://read.qxmd.com/read/31119376/renin-angiotensin-system-inhibitors-for-countering-proteinuria-induced-by-angiogenesis-inhibitors-a-retrospective-observational-analysis
#16
JOURNAL ARTICLE
Toshinori Hirai, Yukari Shuji, Megumi Takiyama, Kazuhiko Hanada, Toshimasa Itoh
PURPOSE: Occurrence of proteinuria could result in cessation of bevacizumab and ramucirumab treatments. Renin-angiotensin system (RAS) inhibitors exert a renoprotective effect by countering proteinuria. However, the association between renoprotective effect of RAS inhibitors and blood pressure control is unclear. This study assessed the risk factors for proteinuria induced by bevacizumab or ramucirumab and the relationship between renoprotective effect of RAS inhibitors and blood pressure control...
May 23, 2019: Cancer Chemotherapy and Pharmacology
https://read.qxmd.com/read/30499710/role-of-renin-angiotensin-system-antagonists-in-the-prevention-of-bevacizumab-and-sunitinib-mediated-cardiac-dysfunction
#17
JOURNAL ARTICLE
Viktoriya Mozolevska, Anna Schwartz, David Cheung, Vineet Goyal, Bilal Shaikh, Bella Dingman, Esther Kim, Ishika Mittal, Chantal Y Asselin, Andrea Edel, Amir Ravandi, James Thliveris, Pawan K Singal, Piotr Czaykowski, Davinder S Jassal
Although anticancer systemic therapy agents clearly lead to improved survival in patients with cancer, these can come at the cost of serious complications including cardiotoxicity. Two types of targeted systemic therapies currently in use for colorectal cancer (CRC) and renal cell cancer (RCC), respectively, include the vascular endothelial growth factor inhibitor bevacizumab (BVZ) and the tyrosine kinase inhibitor sunitinib (SNT). Despite the beneficial effects of BVZ and SNT in improving clinical outcomes in the settings of CRC and RCC, there is an increased risk of cardiac dysfunction...
March 1, 2019: American Journal of Physiology. Heart and Circulatory Physiology
https://read.qxmd.com/read/29792394/concomitant-administration-of-candesartan-cilexetil-in-patients-on-paclitaxel-and-carboplatin-combination-therapy-increases-risk-of-severe-neutropenia
#18
JOURNAL ARTICLE
Yurie Katsube, Daiki Hira, Masayuki Tsujimoto, Hiroyoshi Koide, Tetsuya Minegaki, Yoshito Ikeda, Shin-Ya Morita, Kohshi Nishiguchi, Tomohiro Terada
OBJECTIVE: Angiotensin receptor blockers (ARBs) are often used in patients on paclitaxel (PTX) and carboplatin combination (TC) therapy to treat hypertension caused by the co-administration of bevacizumab. The aim of this retrospective study was to analyze the association between co-administration of ARBs and the development of severe neutropenia in patients on TC therapy. MATERIALS AND METHODS: In this study, 211 concomitant medications were prescribed to 173 patients on TC therapy...
July 2018: International Journal of Clinical Pharmacology and Therapeutics
https://read.qxmd.com/read/29703600/vascular-toxicities-with-vegf-inhibitor-therapies-focus-on-hypertension-and-arterial-thrombotic-events
#19
REVIEW
Rhian M Touyz, Sandra M S Herrmann, Joerg Herrmann
The vascular endothelial growth factor (VEGF) signaling pathway (VSP) fulfills a cardinal role in endothelial cells and its inhibition has profound cardiovascular impact. This is true not only for the normal vasculature but also for the tumor vasculature when VSP inhibitors are used as anti-angiogenic therapies. Generalized endothelial dysfunction predisposes to vasoconstriction, atherosclerosis, platelet activation, and thrombosis (arterial more than venous). All of these have been reported with VSP inhibitors and collectively give rise to vascular toxicities, the most concerning of which are arterial thromboembolic events (ATE)...
June 2018: Journal of the American Society of Hypertension: JASH
https://read.qxmd.com/read/29651572/antiproteinuric-effects-of-renin-angiotensin-inhibitors-in-lung-cancer-patients-receiving-bevacizumab
#20
JOURNAL ARTICLE
Satoru Nihei, Junya Sato, Toshiyuki Harada, Shoichi Kuyama, Toshiro Suzuki, Nobutsugu Waga, Yoshitaka Saito, Shigeki Kisara, Atsuko Yokota, Kouji Okada, Masami Tsuchiya, Kazufumi Terui, Yumiko Tadokoro, Takeshi Chiba, Kenzo Kudo, Satoshi Oizumi, Akira Inoue, Naoto Morikawa
PURPOSE: The objective of this study was to investigate the effect of renin-angiotensin system inhibitors (RASIs) on bevacizumab (BV)-induced proteinuria in non-small cell lung cancer (NSCLC) patients. MATERIALS AND METHODS: We retrospectively reviewed the medical records of NSCLC patients receiving BV between 2008 and 2014 at 11 hospitals. The patients were categorized into three groups according to their antihypertensive drug use: RASI user, non-RASI user, and non-user groups...
June 2018: Cancer Chemotherapy and Pharmacology
keyword
keyword
80324
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.